Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma

David J. Andorsky, MD
Published: Wednesday, Aug 02, 2017



David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

This trial was open to all patients with indolent non-Hodgkin lymphoma. All patients received 12 cycles of induction therapy, consisting of 20 mg daily of lenalidomide and also treatment with rituximab, Andorsky explains. After that 1-year period, patients with stable disease or better were randomized to receive either maintenance therapy with the combination or rituximab alone, which is the standard of care.

In the follicular lymphoma cohort, 160 patients were enrolled, and 50 patients were early relapsers who are known to have a worse prognosis. Double-refractory patients were another 50-or so patients enrolled in this study, he adds. At a median follow-up of 10 months, results showed that for the follicular lymphoma cohort, the overall response rate (ORR) was 66%. For early relapsers and double-refractory patients, the ORR was 45%.


David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

This trial was open to all patients with indolent non-Hodgkin lymphoma. All patients received 12 cycles of induction therapy, consisting of 20 mg daily of lenalidomide and also treatment with rituximab, Andorsky explains. After that 1-year period, patients with stable disease or better were randomized to receive either maintenance therapy with the combination or rituximab alone, which is the standard of care.

In the follicular lymphoma cohort, 160 patients were enrolled, and 50 patients were early relapsers who are known to have a worse prognosis. Double-refractory patients were another 50-or so patients enrolled in this study, he adds. At a median follow-up of 10 months, results showed that for the follicular lymphoma cohort, the overall response rate (ORR) was 66%. For early relapsers and double-refractory patients, the ORR was 45%.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x